Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

• Published in: BMC cancer 2013-04, Vol.13 (1), p.215-215, Article 215
• Main Authors: Müller, Berit Maria, Jana, Lisa, Kasajima, Atsuko, Lehmann, Annika, Prinzler, Judith, Budczies, Jan, Winzer, Klaus-Jürgen, Dietel, Manfred, Weichert, Wilko, Denkert, Carsten
• Format: Article
• Language: English
• Subjects: Biomarkers; Breast cancer; Breast Neoplasms - enzymology; Breast Neoplasms - pathology; Carcinoma, Ductal, Breast - enzymology; Carcinoma, Ductal, Breast - secondary; Carcinoma, Lobular - enzymology; Carcinoma, Lobular - secondary; Cell adhesion & migration; Development and progression; Dilution; Disease Progression; DNA binding proteins; Endocrine therapy; Epigenetic inheritance; Estrogens; Female; Gene expression; Genetic aspects; Histone Deacetylase 1 - metabolism; Histone Deacetylase 2 - metabolism; Histone Deacetylases - metabolism; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Pathology; Patients; Physiological aspects; Prognosis; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Statistical analysis; Tissue Array Analysis; Transferases; Tumors
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-13-215

In breast cancer, the role of epigenetic alterations including modifications of the acetylation status of histones in carcinogenesis has been an important research focus during the last years. An increased deacetylation of histones leads to increased cell proliferation, cell migration, angiogenesis and invasion. Class 1 histone deacetylases (HDAC) seem to be most important during carcinogenesis. The immunhistochemical expression of HDAC1, 2 and 3 was analyzed on tissue microarrays (TMAs) from 238 patients with primary breast cancer. We analyzed the nuclear staining intensity (negative, weak, moderate, strong) as well as the percentage of positive tumor cells and calculated the immunoreactivity score (0-12). Expression was correlated with clinicopathological parameters and patient survival. In this cohort, we found a differential positive expression of HDAC1, HDAC2 and HDAC3. HDAC2 and HDAC3 expression was significantly higher in less differentiated tumors: HDAC2 (n=207), p